Patents by Inventor Bengt Erik Haug
Bengt Erik Haug has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200323888Abstract: The present invention relates to compounds having the formula [Co-enzyme A or analogue thereof]-Z1-Z2-Z3-Z4, wherein Z1 is a linker, Z2 and Z3 are peptides or peptide-based moieties, and Z4 is a C-terminal group. The invention also provides pharmaceutical compositions comprising compounds of the invention, and their uses for the treatment of cancer, wound healing and nerve regeneration, inter alia.Type: ApplicationFiled: December 19, 2018Publication date: October 15, 2020Applicant: VESTLANDETS INNOVASJONSSELSKAP ASInventors: Thomas ARNESEN, Bengt Erik HAUG, Line Merethe MYKLEBUST, Havard FOYN
-
Publication number: 20160176923Abstract: The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumour agents.Type: ApplicationFiled: December 14, 2015Publication date: June 23, 2016Inventors: Bengt Erik Haug, Jon Amund Eriksen, John Sigurd Svendsen, Oystein Rekdal
-
Patent number: 9241968Abstract: The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumor agents.Type: GrantFiled: September 11, 2009Date of Patent: January 26, 2016Assignee: Lytix Biopharma ASInventors: Bengt Erik Haug, Jon Amund Eriksen, John Sigurd Svendsen, Oystein Rekdal
-
Patent number: 9115169Abstract: The invention provides a method of treating tumors by adminstering to a human or animal patient an effective amount of a molecule of 2 to 4 amino acids or equivalent subunits in length, which incorporates a bulky and lipophilic group comprising at least 13 non-hydrogen atoms and containing no more than 2 polar functional groups, in which the bulky and lipophilic group incorporates one or more closed rings of 5 or more non-hydrogen atoms, and in which the molecule further has at least two more cationic than anionic moieties.Type: GrantFiled: September 22, 2011Date of Patent: August 25, 2015Assignee: Lytix Biopharma ASInventors: John Sigurd Svendsen, Bengt Erik Haug, Istvan Marko, Øystein Rekdal, Merete Linchausen Skar, Wenche Stensen, Morten Bøhmer Strøm
-
Publication number: 20120149908Abstract: In a first aspect, the present invention relates to a method for the preparation of alkynylpiperidine and alkynylpiperidine derivatives. In particular, a method is provided for preparing alkynylpiperidine derivatives starting from epoxide compounds. Further, the alkynylpiperidine derivatives according to the present inventions are substituted trans-3-4-alkynylpiperidine derivatives. In another aspect, triazolylpiperidine compounds and methods for said preparation are provided. In particular, the triazolylpiperidine compounds according to the present invention are obtained by reacting an alkynylpiperidine derivatives with an organic azid, preferably, in the presence of a Cu (I) or Ru catalyst. In a preferred embodiment, 1,4-disubstituted or 1,5-disubstituted 1,2,3-triazolylpiperidine compounds are provided.Type: ApplicationFiled: December 13, 2011Publication date: June 14, 2012Inventors: Leiv K. Sydnes, Bengt Erik Haug, Rianne Harmsen
-
Publication number: 20120108520Abstract: The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilising microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics.Type: ApplicationFiled: September 22, 2011Publication date: May 3, 2012Applicant: LYTIX BIOPHARMA ASInventors: John Sigurd Svendsen, Bengt Erik Haug, Istvan Marko, Øystein Rekdal, Merete Linchausen Skar, Wenche Stensen, Morten Bøhmer Strøm
-
Publication number: 20110318364Abstract: The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumour agents.Type: ApplicationFiled: September 11, 2009Publication date: December 29, 2011Applicant: LYTIX BIOPHARMA ASInventors: Bengt Erik Haug, Jon Amund Eriksen, John Sigurd Svendsen, Oystein Rekdal
-
Patent number: 8048852Abstract: The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilizing microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics.Type: GrantFiled: April 20, 2007Date of Patent: November 1, 2011Assignee: Lytix Biopharma ASInventors: John Sigurd Svendsen, Bengt Erik Haug, Istvan Marko, Øystein Rekdal, Merete Linchausen Skar, Wenche Stensen, Morten Bøhmer Strøm
-
Publication number: 20100267621Abstract: The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilising microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics.Type: ApplicationFiled: April 20, 2007Publication date: October 21, 2010Applicant: LYTIX BIOPHARMA ASInventors: John Sigurd Svendsen, Bengt Erik Haug, Istvan Marko, Oystein Rekdal, Merete Linchausen Skar, Wenche Stensen, Morten Bohmer Strom
-
Patent number: 7232803Abstract: The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilizing microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics.Type: GrantFiled: March 9, 2001Date of Patent: June 19, 2007Assignee: Lytix Biopharma ASInventors: John Sigurd Svendsen, Bengt Erik Haug, Istvan Marko, Øystein Rekdal, Merete Linchausen Skar, Wenche Stensen, Morten Bøhmer Strøm
-
Publication number: 20030195144Abstract: The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipoophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilising microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics.Type: ApplicationFiled: February 27, 2003Publication date: October 16, 2003Inventors: John Sigurd Svendsen, Bengt Erik Haug, Istvan Marko, Oystein Rekdal, Merete Linchausen Skar, Wenche Stensen, Morten Bohmer Strom